-
FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC
19 Apr 2024 21:32 GMT
… The FDA has approved alectinib (Alecensa; Genentech) for adjuvant treatment … results from phase 3 ALINA trial (NCT03456076), a randomized, … infection, fatigue, rash, and cough. According to experts, the … , head of Global Product Development, Roche, in the press …
-
FDA approves Alecensa for certain patients with ALK-positive lung cancer
19 Apr 2024 19:32 GMT
… Healio
The FDA approved alectinib as an adjuvant treatment for patients … a phase 3 randomized trial that showed prolonged disease- … -19, fatigue, rash and cough. Patients taking alectinib could be … a higher risk [for] developing brain metastases than those with …
-
FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease
19 Apr 2024 21:32 GMT
… was FDA approved in September 2023 for maintenance treatment for … press release. “Our development of a subcutaneous option … double-blind, placebo-controlled trial, VISIBLE 2 Study ( … respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain …
-
Map shows ‘100-day cough’ hotspots as UK cases surge 40% in a week
19 Apr 2024 19:30 GMT
… to serious complications requiring hospital treatment.
One baby died of … conclusions.
What is whooping cough?
Whooping cough is a bacterial infection … .
But later, it can develop into bouts of coughing that … ‘lab rats’ in clinical trials which gave them hep C …
-
Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease
19 Apr 2024 19:33 GMT
… Entyvio Pen.
The FDA has approved subcutaneous administration … double-blind, placebo-controlled trial assessing the safety and … respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain … treatment at home or on-the-go. Our development …
-
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
18 Apr 2024 23:08 GMT
… double-blind, placebo-controlled trial, which assessed the … respiratory tract infection, fatigue, cough, bronchitis, influenza, back … who develop a severe infection while on treatment with … prescription drugs including the ones under development.
References …
-
FDA Approves Alecensa for ALK-Positive NSCLC
18 Apr 2024 22:33 GMT
… Administration (FDA) has approved Alecensa (alectinib) for the treatment of patients … a higher risk of developing brain metastases than those … exploratory analysis of the trial also showed an improvement … -19, fatigue, rash and cough.
For more news on cancer …
-
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
18 Apr 2024 21:57 GMT
… Genentech, Inc.) for adjuvant treatment following tumor resection in … global, randomized, open-label trial (ALINA, NCT03456076) in … , fatigue, rash, and cough.
The recommended alectinib dose … oncology drugs among international partners. For this review, FDA …
-
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
18 Apr 2024 21:08 GMT
… (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following … Alecensa in this trial were generally consistent … , shortness of breath, cough, or fever.
Kidney problems … company that discovers, develops, manufactures and commercializes …
-
Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
18 Apr 2024 15:39 GMT
… regimen proved the superiority of treatment with upadacitinib among this … with immune-mediated diseases by developing new treatments where significant medical needs … respiratory tract infections, shingles, nausea, cough, headache, abdominal pain, fatigue, …